07:00 , Oct 9, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Brain cancer MicroRNA-33a (miR-33a); phosphodiesterase-8A (PDE-8A); UV radiation resistance associated (UVRAG) Studies in patient samples and mice suggest antagonizing miR-33a could help treat brain cancer....
08:00 , Dec 12, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Cardiovascular disease MicroRNA-33a (miR-33a); miR-33b Mouse and primate studies suggest an 8mer anti-miRNA that targets both miR-33a and miR-33b could...
08:00 , Dec 12, 2013 |  BC Innovations  |  Tools & Techniques

Family seeds

It has been long assumed that the specificity of microRNA inhibitors is determined by length-dogma held that anti-miRNAs should be more than 16 nucleotides and approximate the length of the actual miRNA targets. Now, an...
07:00 , Oct 27, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Cardiovascular disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Cardiovascular disease Atherosclerosis MicroRNA-33a (miR-33a); miR-33b Primate studies suggest antagonizing miR-33a and miR-33b could help treat atherosclerosis. In African green monkeys, an antisense miRNA inhibiting both...
07:00 , Apr 4, 2011 |  BC Week In Review  |  Company News

Regulus, New York University deal

Regulus received exclusive rights to the university's IP covering methods of use in modulating microRNA-33a (miR-33a) and microRNA-33b (miR-33b) for metabolic diseases. Regulus is developing several candidates that target miRNAs including an oligonucleotide that targets...